rss
Br J Ophthalmol 2008;92:705-711 doi:10.1136/bjo.2007.133587
  • Laboratory science
    • Original Article

Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle

  1. L Cheng1,
  2. E Anglin2,
  3. F Cunin3,
  4. D Kim2,
  5. M J Sailor2,
  6. I Falkenstein1,
  7. A Tammewar1,
  8. W R Freeman1
  1. 1
    Jacobs Retina Center at Shiley Eye Center, UCSD, La Jolla, CA, USA
  2. 2
    Department of Chemistry and Biochemistry, UCSD, La Jolla, CA, USA
  3. 3
    Laboratoire de Matériaux Catalytiques et Catalyse en Chimie Organique, UMR5618 ENSCM-CNRS-UMI, Institut Gerhardt, Montpellier, France
  1. Dr L Cheng, Jacobs Retina Center at Shiley Eye Center, UCSD, 9415 Campus Point Drive, La Jolla, CA 92037-0946, USA; cheng{at}eyecenter.ucsd.edu
  • Accepted 28 January 2008

Abstract

Aim: To determine the suitability of porous silicon photonic crystals for intraocular drug-delivery.

Methods: A rugate structure was electrochemically etched into a highly doped p-type silicon substrate to create a porous silicon film that was subsequently removed and ultrasonically fractured into particles. To stabilise the particles in aqueous media, the silicon particles were modified by surface alkylation (using thermal hydrosilylation) or by thermal oxidation. Unmodified particles, hydrosilylated particles and oxidised particles were injected into rabbit vitreous. The stability and toxicity of each type of particle were studied by indirect ophthalmoscopy, biomicroscopy, tonometry, electroretinography (ERG) and histology.

Results: No toxicity was observed with any type of the particles during a period of >4 months. Surface alkylation led to dramatically increased intravitreal stability and slow degradation. The estimated vitreous half-life increased from 1 week (fresh particles) to 5 weeks (oxidised particles) and to 16 weeks (hydrosilylated particles).

Conclusion: The porous silicon photonic crystals showed good biocompatibility and may be used as an intraocular drug-delivery system. The intravitreal injectable porous silicon photonic crystals may be engineered to host a variety of therapeutics and achieve controlled drug release over long periods of time to treat chronic vitreoretinal diseases.

Footnotes

  • Funding: (1) Unrestricted research fund to Jacobs Retina Center, UCSD (Freeman & Cheng). (2) Supported in part by Research to Prevent Blindness (Freeman). (3) National Science Foundation, Grant# DMR-0503006 (MJS). MJS is a member of the Moores UCSD Cancer Center and the UCSD NanoTUMOR Center under which this research was conducted and partially supported by NIH grant U54 CA 119335. The CNRS/DREI program (call for proposal CNRS/United States 2005 #3312) is also acknowledged for financial support.

  • Competing interests: UCSD has filed a provisional patent for this intraocular drug-delivery system.

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.